Structure Therapeutics (NASDAQ:GPCR) Shares Up 6% – What’s Next?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price shot up 6% during trading on Wednesday . The stock traded as high as $21.99 and last traded at $22.39. 59,438 shares changed hands during trading, a decline of 93% from the average session volume of 838,890 shares. The stock had previously closed at $21.11.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. William Blair started coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities reiterated a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus began coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Performance

The stock’s 50 day simple moving average is $24.88 and its 200 day simple moving average is $31.95. The firm has a market cap of $1.25 billion, a P/E ratio of -29.55 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd grew its holdings in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after buying an additional 553 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after acquiring an additional 1,122 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Structure Therapeutics during the 4th quarter worth $34,000. FNY Investment Advisers LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter worth $40,000. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock valued at $61,000 after purchasing an additional 455 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.